Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. more
Time Frame | RVNC | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.32% | -2.12% | -3% |
1-Month Return | -18.68% | -3.42% | -0.73% |
3-Month Return | -46.82% | -11.13% | 2.87% |
6-Month Return | 7.67% | -5.74% | 7.17% |
1-Year Return | -59.23% | 3.97% | 25.31% |
3-Year Return | -81.51% | 1.05% | 28.38% |
5-Year Return | -80.96% | 34.37% | 81.89% |
10-Year Return | -82.49% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 413.00K | 15.32M | 77.80M | 132.56M | 234.04M | [{"date":"2019-12-31","value":0.18,"profit":true},{"date":"2020-12-31","value":6.55,"profit":true},{"date":"2021-12-31","value":33.24,"profit":true},{"date":"2022-12-31","value":56.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 102.86M | 4.77M | 23.41M | 51.67M | 152.16M | [{"date":"2019-12-31","value":67.6,"profit":true},{"date":"2020-12-31","value":3.13,"profit":true},{"date":"2021-12-31","value":15.38,"profit":true},{"date":"2022-12-31","value":33.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (102.45M) | 10.56M | 54.39M | 80.90M | 81.88M | [{"date":"2019-12-31","value":-125.12,"profit":false},{"date":"2020-12-31","value":12.89,"profit":true},{"date":"2021-12-31","value":66.43,"profit":true},{"date":"2022-12-31","value":98.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (24805.81%) | 68.88% | 69.91% | 61.03% | 34.98% | [{"date":"2019-12-31","value":-35482.87,"profit":false},{"date":"2020-12-31","value":98.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":87.29,"profit":true},{"date":"2023-12-31","value":50.04,"profit":true}] |
Operating Expenses | 164.87M | 283.72M | 329.06M | 353.07M | 398.65M | [{"date":"2019-12-31","value":41.36,"profit":true},{"date":"2020-12-31","value":71.17,"profit":true},{"date":"2021-12-31","value":82.54,"profit":true},{"date":"2022-12-31","value":88.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (164.46M) | (273.16M) | (274.68M) | (272.17M) | (316.78M) | [{"date":"2019-12-31","value":-16445900000,"profit":false},{"date":"2020-12-31","value":-27316200000,"profit":false},{"date":"2021-12-31","value":-27467600000,"profit":false},{"date":"2022-12-31","value":-27216900000,"profit":false},{"date":"2023-12-31","value":-31677700000,"profit":false}] |
Total Non-Operating Income/Expense | 10.56M | (22.37M) | (12.57M) | (25.35M) | (11.74M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-211.83,"profit":false},{"date":"2021-12-31","value":-119.01,"profit":false},{"date":"2022-12-31","value":-239.98,"profit":false},{"date":"2023-12-31","value":-111.12,"profit":false}] |
Pre-Tax Income | (159.43M) | (284.71M) | (281.31M) | (355.72M) | (323.69M) | [{"date":"2019-12-31","value":-15942900000,"profit":false},{"date":"2020-12-31","value":-28470900000,"profit":false},{"date":"2021-12-31","value":-28131000000,"profit":false},{"date":"2022-12-31","value":-35572200000,"profit":false},{"date":"2023-12-31","value":-32368600000,"profit":false}] |
Income Taxes | (3.21M) | (2.62M) | 5.51M | 700.00K | 300.00K | [{"date":"2019-12-31","value":-58.25,"profit":false},{"date":"2020-12-31","value":-47.52,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.69,"profit":true},{"date":"2023-12-31","value":5.44,"profit":true}] |
Income After Taxes | (156.22M) | (282.09M) | (286.82M) | (356.42M) | (323.99M) | [{"date":"2019-12-31","value":-15621700000,"profit":false},{"date":"2020-12-31","value":-28208900000,"profit":false},{"date":"2021-12-31","value":-28682400000,"profit":false},{"date":"2022-12-31","value":-35642200000,"profit":false},{"date":"2023-12-31","value":-32398600000,"profit":false}] |
Income From Continuous Operations | (159.43M) | (282.09M) | (281.31M) | (356.42M) | (414.24M) | [{"date":"2019-12-31","value":-15942900000,"profit":false},{"date":"2020-12-31","value":-28208900000,"profit":false},{"date":"2021-12-31","value":-28131000000,"profit":false},{"date":"2022-12-31","value":-35642200000,"profit":false},{"date":"2023-12-31","value":-41423900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (156.22M) | (282.09M) | (286.82M) | (356.42M) | (323.99M) | [{"date":"2019-12-31","value":-15621700000,"profit":false},{"date":"2020-12-31","value":-28208900000,"profit":false},{"date":"2021-12-31","value":-28682400000,"profit":false},{"date":"2022-12-31","value":-35642200000,"profit":false},{"date":"2023-12-31","value":-32398600000,"profit":false}] |
EPS (Diluted) | (3.66) | (4.83) | (4.18) | (3.94) | (3.79) | [{"date":"2019-12-31","value":-366,"profit":false},{"date":"2020-12-31","value":-483,"profit":false},{"date":"2021-12-31","value":-418,"profit":false},{"date":"2022-12-31","value":-394,"profit":false},{"date":"2023-12-31","value":-379,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RVNC | |
---|---|
Cash Ratio | 2.30 |
Current Ratio | 4.12 |
Quick Ratio | 3.05 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RVNC | |
---|---|
ROA (LTM) | -24.36% |
ROE (LTM) | -2096.78% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RVNC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.35 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.35 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RVNC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.26 |
P/B | 12.30 |
Price/FCF | NM |
EV/R | 2.42 |
EV/Ebitda | NM |
PEG | NM |
Revance The (RVNC) share price today is $3.09
Yes, Indians can buy shares of Revance The (RVNC) on Vested. To buy Revance The from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RVNC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Revance The (RVNC) via the Vested app. You can start investing in Revance The (RVNC) with a minimum investment of $1.
You can invest in shares of Revance The (RVNC) via Vested in three simple steps:
The 52-week high price of Revance The (RVNC) is $9.74. The 52-week low price of Revance The (RVNC) is $2.3.
The price-to-earnings (P/E) ratio of Revance The (RVNC) is
The price-to-book (P/B) ratio of Revance The (RVNC) is 12.30
The dividend yield of Revance The (RVNC) is 0.00%
The market capitalization of Revance The (RVNC) is $320.48M
The stock symbol (or ticker) of Revance The is RVNC